[
    [
        {
            "time": "2023-11-07",
            "original_text": "高瓴再出手！8亿亏损能否助力加科思癌症疗法走向新纪元？ 亏损",
            "features": {
                "keywords": [
                    "高瓴",
                    "癌症疗法",
                    "亏损",
                    "加科思"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "高瓴再出手！8亿亏损能否助力加科思癌症疗法走向新纪元？ 亏损",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
            "features": {
                "keywords": [
                    "医药生物",
                    "冠脉支架",
                    "国采",
                    "头部企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
            "features": {
                "keywords": [
                    "医药生物",
                    "流感",
                    "肺炎",
                    "疫苗",
                    "三季报"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "创业板指跌幅扩大至1%，乐普医疗、贝达药业、欧普康视、康龙化成领跌",
            "features": {
                "keywords": [
                    "创业板指",
                    "乐普医疗",
                    "贝达药业",
                    "欧普康视",
                    "康龙化成"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "创业板指跌幅扩大至1%，乐普医疗、贝达药业、欧普康视、康龙化成领跌",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]